Skip to main content
Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study

Fig. 1

Most common adverse events by grade. A Any-grade treatment-emergent adverse events occurring in > 20% of all patients. B Grade 3/4 adverse events occurring in > 5% of all patients. Patient numbers are shown within the bars. aAEs of infection were bronchitis (n = 1), candida infection (n = 1), cellulitis (n = 1), fungal abscess central nervous system (n = 1, recovered), infection (not specified, n = 1), pneumonia (n = 2), sepsis (n = 1), staphylococcal bacteremia (n = 1), upper respiratory tract infection (n = 1), and urinary tract infection (n = 1)

Back to article page